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Numerous phenolic compounds have been reported to have an inhibitory role on amyloid
formation of proteins. The present study, utilizing lysozyme as a model system, examined the
anti-amyloidogenic effects of phenol and three diphenol epimers. The results indicated that
catechol and hydroquinone dose-dependently inhibited lysozyme ﬁbrillation and covalently
bound to the peptide chains to form quinoproteins, showing a similar effect to benzoquinone.
In contrast, phenol and resorcinol did not modify the peptide with a quinone moiety, showing
no effect on lysozyme ﬁbrillation. We suggest that quinone intermediates are the active form
for a phenolic compound to inhibit lysozyme ﬁbrillation. The modiﬁcation of lysozyme with
quinone moieties alters the interacting forces between peptide chains and consequently interrupts
the process of lysozyme ﬁbrillation.
Structured summary of protein interactions:
Lysozyme and Lysozyme bind by ﬂuorescence technology (View interaction).
Lysozyme and Lysozyme bind by transmission electron microscopy (View interaction).
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mounting evidences indicate that amyloid ﬁbrillation of pro-
teins play an important role in amyloid-related diseases, including
Alzheimer’s disease, prion diseases, and type 2 diabetes [1–3].
These proteins, despite their unrelated amino acid sequences and
tertiary structures, can unfold and assembly into ﬁbrils with simi-
lar ultrastructures and identical biochemical properties, including
long and unbranched ﬁbrils with enriched b-sheet structure,
increased surface hydrophobicity, ﬂuorescence upon binding to
thioﬂavin T (ThT) and the ability to disrupt cellular membranes.
Human lysozyme with point mutations has been reported to be
associated with the non-neuropathic systemic amyloidosis [4].
The amyloid ﬁbrils formed by the wild-type of lysozyme in vitro
shared similar ultrastructures and biochemical properties with
those extracted from pathological deposits in tissue. Hen egg-
white lysozyme (referred to as lysozyme in this article), a small
global protein with a single chain that consists of 129 amino acid
residues and four disulﬁde linkages, is a well-characterized proteinchemical Societies. Published by E
NBT, nitroblue tetrazolium;
ine T
eng).and has been used as an alternative in vitro model for studying
amyloidogenesis of a protein. Under in vitro conditions of low pH
and elevated temperature, lysozyme is able to transform into amy-
loid ﬁbrils with typical ﬁbrillar morphology and increased binding
capacities for ThT and Congo Red [5]. Recent investigations showed
that the synthetic lysozyme ﬁbrils exhibited non-enzymatic cyto-
toxicity, including inducing aggregation and hemolysis of human
erythrocytes, triggering intermolecular cross-linking of cytoskele-
tal proteins and reducing the viability of neuroblastoma cells
through apoptotic and necrotic pathways [6–8].
Inhibition of amyloid formation and disruption of the formed
ﬁbrillar assemblies are the therapeutic strategies proposed for
the treatment of amyloid-related diseases. Enzymatic inhibitors,
hormones, antagonists, antibodies, peptide fragments, synthetic li-
gands and natural polyphenols have been investigated extensively
to screen anti-amyloidogenic candidates. Many polyphenolic com-
pounds showed effective roles in inhibition of amyloid formation
and disruption of preformed amyloid ﬁbrils. Weak forces between
inhibitor and peptide chains, including hydrogen bonding, hydro-
phobic and aromatic interactions, have been suggested to be the
driving forces in the anti-amyloidogenic role of polyphenols [9–
11]. Furthermore, antioxidant capacities are also thought to be
involved in the anti-amyloidogenic activity of polyphenols [12].
Hirohata et al. found that the oxidative form of a polyphenol hadlsevier B.V. All rights reserved.
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form [13].
Despite extensive investigations on the inhibitory effects of
polyphenols on amyloidogenesis, the detailed molecular mecha-
nism is still unclear and remains further investigation. To explore
the structure–activity relationship of polyphenol against amyloido-
genesis, the present study investigates the inhibitory effects of four
structure-related phenolic compounds, phenol, catechol, resorcinol
and hydroquinone (Fig. 1) on amyloid formation by utilizing lyso-
zyme as an in vitro model. These phenols have a monocyclic struc-
ture, one or two hydroxyl groups and small molecular weights,
possessing similar capacities of hydrophobic interaction, aromatic
stacking and hydrogen bonding in their interaction with polypep-
tide chains. Therefore this model is conducive to elucidate the
importance of antioxidant potency in the anti-amyloidogenic activ-
ity of a phenol. The results suggest that the formation of quinone
intermediates via oxidation is a prerequisite for a phenolic com-
pound to inhibit lysozyme ﬁbrillation. The role of benzoquinone
on the amyloid formation of lysozyme has also been investigated
for a comparison with the effects of phenolic compounds.
2. Materials and methods
2.1. Chemicals
Hen egg white lysozyme (MW 14.3 kDa), ThT and nitroblue tet-
razolium (NBT) were purchased from Sigma & Aldrich (St. Louis,
MO, USA); p-benzoquinone and phenolic compounds were from
Fluka (Buchs, Switzerland). Electrophoresis related reagents were
from Bio-Rad (Hercules, CA). Other reagents were of analytical
grade.
2.2. Preparation and characterization of lysozyme ﬁbrils
Lysozyme ﬁbrils were prepared according to our previous
report with minor modiﬁcation [6]. Brieﬂy, 100 mg hen egg white
lysozyme was dissolved in 10 ml HCl solution (10 mM, pH 2.0)
with or without a phenolic compound or benzoquinone to a ﬁnal
concentration of 10 mg/ml. The concentrations of phenolic com-
pounds and benzoquinone were 0–100 lg/ml. The mixture was
incubated for 12–15 days at 65 C in a water-bath without agita-
tion. The growth of lysozyme ﬁbril was monitored by ThT ﬂuores-
cence and transmission electron microscopy (TEM). ThT
ﬂuorescence was measured in a mixture of 33 lg/ml lysozyme
and 10 lM ThT, with excitation at 440 nm and emission at
484 nm in a Perkin Elmer LS55 spectroﬂuorimeter. For TEM mea-
surements, an aliquot of lysozyme ﬁbrils was diluted 20-fold with
water and dropped onto copper-mesh grids. Samples were nega-
tively stained with 2% (w/v) uranyl acetate and air-dried at room
temperature. Observations were carried out using a JOEL JEM-
2100 electron microscope with an accelerating voltage of 80 kV.
2.3. Gel electrophoresis and NBT staining assay
SDS–PAGE was performed in Tricine buffer (pH 8.2) by using a
5% stacking gel and a 15% separating gel. To each lane 30 lgFig. 1. Molecular structures of inhibitors tested in this study. Phenol (P), catechol
(C), resorcinol (R), hydroquinone (H) and benzoquinone (B).protein was applied. Bands were visualized by Coomassie brilliant
blue R-250 staining. For blotting assay, the gel bands were trans-
ferred onto a polyvinylidene ﬂuoride membrane (0.45 lm, Millip-
ores) with a mini transfer cell (GE Healthcare). Quinoproteins
were detected by staining the membrane with NBT (0.24 mM in
2 M potassium glycinate, pH 10). The blotting membrane was
immersed in the glycinate/NBT solution for 45 min in the dark,
resulting in a blue-purple stain of quinoprotein bands and no
staining of other peptides.
3. Results and discussion
3.1. The inhibitory effects of phenolic compounds on lysozyme
ﬁbrillation
Incubation of lysozyme under conditions of low pH and ele-
vated temperature resulted in formation of amyloid ﬁbrils.
Increased temperature, ionic strength or lysozyme concentration
signiﬁcantly shortened the lag time of ﬁbril growth [5,6]. In the
present study, we incubated 10 mg/ml lysozyme in 10 mM HCl
solution (pH 2.0) at 65 C in the presence or absence of an inhibitor.
The growth of amyloid ﬁbrils was monitored and characterized by
ThT ﬂuorescence and transmission electron microscopy.
ThT is a ﬂuorescent probe for monitoring the formation and
growth of amyloid ﬁbrils. The ﬂuorescence intensity of ThT
increased signiﬁcantly when the compound speciﬁcally binding
to the highly ordered b-sheet structure of amyloid ﬁbrils [14]. As
depicted in Fig. 2A, an increase in ThT ﬂuorescence emission was
observed after incubating the control sample for 3 days. The
intensity of ThT ﬂuorescence increased gradually as the amyloid
formation progressed until reached to a plateau after 12 days of
incubation. In the presence of phenol or resorcinol (100 lg/ml),
the ThT proﬁles showed similar pattern as that of the control
experiment, indicating that these two compounds had no effect
on lysozyme ﬁbrillation. In contrast, the o- and p-isomers of diphe-
nol, catechol and hydroquinone, exhibited inhibitory effects on
amyloid formation of lysozyme in a dose-dependent fashion. For
instance, co-incubation of lysozyme with 25, 50 and 100 lg/ml of
catechol resulted in a reduction in ThT ﬂuorescence of mature
ﬁbrils 21.2%, 33.3% and 68.9%, respectively (Fig. 2B).
The inhibitory effects of catechol and hydroquinone on lyso-
zyme ﬁbrillation were supported by TEM determination of the
ﬁbrils. Fig. 3A–E shows the TEM images of lysozyme assemblies
aged 12 days prepared in the presence or absence of phenols. In
the absence of a phenolic compound, the matured lysozyme ﬁbrils
showed a typical amyloid morphology, characterized as long,
straight and dense ﬁbrils with diameters of 8–30 nm (Fig. 3A). In
the presence of phenol (Fig. 3B) and resorcinol (Fig. 3C), the lyso-
zyme ﬁbrils showed similar morphologies to the control ﬁbrils.
In contrast, incubation of lysozyme with catechol or hydroquinone
resulted in a noticeable reduction of amyloid ﬁbrils. The resultant
ﬁbrils coexisted with amorphous particles and a few ‘‘beads-on-
string’’ protoﬁbrils [6,15], as shown in Fig. 3D and E.
In general, the redox potentials of the phenolic compounds
tested in this study have an order of phenol > resorcinol > cate-
chol–hydroquinone [16], suggesting that catechol and hydroqui-
none are more susceptible to oxidative stress than resorcinol and
phenol. In addition, catechol and hydroquinone, rather than resor-
cinol, are able to form stable quinone intermediates upon oxida-
tion. The fact that catechol and hydroquinone rather than
resorcinol or phenol inhibited amyloid formation implicated that
an oxidative intermediate, most likely in a quinone form, possibly
involved in the anti-amyloidogenic activity of phenols. To support
this hypothesis, the effect of benzoquinone on lysozyme ﬁbrillation
was analyzed by ThT assay and TEM. As depicted in Fig. 2A, almost
no increase in ThT ﬂuorescence was observed when co-incubation
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Fig. 2. Inhibitory effects of phenols and benzoquinone on amyloid formation of
lysozyme. (A) The ThT growth curves of lysozyme ﬁbrils in the absence or presence
of inhibitors (100 lg/ml). (B) Dose-dependence of amyloid inhibition by catechol,
hydroquinone and benzoquinone. Lysozyme (10 mg/ml) was incubated with the
inhibitors at 65 C for 12 days.
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Fig. 3. TEM images of lysozyme assemblies. Samples were prepared by incubating
lysozyme (10 mg/ml) at 60 C for 12 days in the absence (A) and presence of 100 lg/
ml phenol (B), resorcinol (C), catechol (D), hydroquinone (E) and benzoquinone (F).
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Fig. 4. SDS–PAGE and NBT-staining assay of lysozyme assemblies aged 12 days. (A)
SDS–PAGE of lysozyme assemblies prepared in the absence (lane 2) and presence of
100 lg/ml phenol (lane 3), resorcinol (lane 4), catechol (lane 5), hydroquinone (lane
6) and benzoquinone (lane 7). Native lysozyme monomer (14.3 kDa, as pointed by
the arrow) was applied in lane 1. Small-size peptide fragments can be observed in
lanes 2–7 without obvious difference. (B) The NBT-staining results of lysozyme
assemblies. The samples have same order as in (A). Samples were subjected to
electrophoresis and then the bands on the gel were transferred onto a blotting
membrane and followed by redox-cycling staining with NBT/glycinate. Quinone-
modiﬁed peptides can be observed in the catechol- (lane 5), hydroquinone- (lane 6)
and benzoquinone-containing (lane 7) samples.
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TEM determination of the sample showed that only amorphousparticles and ‘‘beads-on-string’’ protoﬁbrils were formed (Fig. 3F),
indicating that 100 lg/ml benzoquinone completely inhibited
amyloid formation of lysozyme. The inhibition of amyloid forma-
tion by benzoquinone was also dose-dependent. Incubation of
lysozyme with 25 lg/ml benzoquinone resulted in a 73.4% reduc-
tion in ThT ﬂuorescence intensity (Fig. 2B), showing a stronger
inhibitory effect than that of catechol and hydroquinone.
3.2. Phenols inhibited amyloid ﬁbrillation via quinone intermediates
There is considerable evidence showed that reactive quinonoid
species could covalently bind to proteins [17–19]. Incubation of
catechol and hydroquinone at 65 C could result in the formation
of reactive quinone intermediates which reacted with lysozyme.
To probe whether quinone intermediates formed during the incu-
bation, NBT-staining assays were performed for detecting the qui-
none-modiﬁed peptides. At an alkaline pH, quinones and related
quinonoid substances can catalyze a redox cycling by which NBT
is reduced to the blue-purple insoluble formazan, allowing the
detection of quinoproteins on a blotting membrane [20]. Fig. 4A
showed the SDS–PAGE patterns of lysozyme incubated for 12 days
in the absence and presence of a phenolic compound or benzoqui-
none. In the presence of SDS, the ﬁbrilar species could be disaggre-
gated and separated into lysozyme monomers and small-size
peptide fragments originated from acidic hydrolysis of the protein
[21]. In the presence of phenols or benzoquinone, the SDS–PAGE
patterns (Fig. 4A, lanes 3–7) are similar to that of the control sam-
ple (Fig. 4A, lane 2), indicating that amyloid formation is not re-
lated to the fragmentation of lysozyme via acidic hydrolysis.
A parallel SDS–PAGE experiment was performed and the gel
bands were electrically transferred onto a polyvinylidene ﬂuoride
membrane prior to detection of quinoproteins by NBT staining.
As shown in Fig. 4B, quinone-modiﬁed peptides were observed in
lanes 5, 6 and 7, to which the samples containing catechol, hydro-
quinone and benzoquinone were applied respectively. This fact
indicated that incubation of catechol and hydroquinone resulted
in the formation of reactive quinone intermediates which cova-
lently bound to the peptide chains. Considering that phenol and
resorcinol neither modiﬁed the peptides with quinone moieties
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formation of reactive quinone intermediates is a prerequisite for a
phenolic compound to inhibit amyloid ﬁbrillation of lysozyme.
Benzoquinone demonstrated a higher inhibitory activity than
catechol and hydroquinone in inhibition of amyloid formation of
lysozyme (Fig. 2) probably due to that benzoquinone provided
more reactive quinone species than the diphenols. Fig. 5 shows
the SDS–PAGE patterns (A, B and C) and the blotting results (D, E
and F) of lysozyme incubated for 0–12 days in the presence of cat-
echol, hydroquinone and benzoquinone. In the presence of benzo-
quinone, quinoproteins can be observed at the early stage of
incubation (1–4 days), as shown in lanes 2–4, Fig 5F. In contrast,
the NBT staining of lysozyme co-incubated with catechol and
hydroquinone for 6 days are still weak (lane 5, Fig 5D and E), impli-
cating that the formation of quinoproteins in these samples relied
on the accumulation of quinone species originated from the degra-
dation of diphenols. The results of the present study suggest that
the more lysozyme is modiﬁed with quinones, the less amyloid ﬁ-
brils form. Therefore, we conclude that quinone intermediates play
a key role in the inhibitory activity of phenolic compounds on amy-
loid formation of lysozyme.
Numerous polyphenolic compounds, particularly natural poly-
phenols, have been reported to possess destabilizing effect on
preformed amyloid ﬁbrils. In previous work, we found that 92%
preformed lysozyme ﬁbrils were converted into amorphous
aggregates when incubating the ﬁbrils (500 lg/ml) with green
tea epigallocatechin-3-gallate (EGCG) (100 lg/ml) for 12 h at
room temperature [22]. Under the same condition, the values
for catechol, hydroquinone and benzoquinone were 10.7%,
13.5% and 15.5%, respectively. Phenol and resorcinol did not
show any effect on the mature ﬁbrils. In contrast to higher
inhibitory effect on amyloid formation than catechol and hydro-
quinone, benzoquinone showed a similar amyloid-destabilizing
role to the diphenols, suggesting that the mechanism of destabi-
lizing ﬁbrils may be different from that of inhibiting amyloid
formation. It remains further exploration whether the ﬁbril-
destabilizing role of catechol and hydroquinone involves quino-
protein formation.
Several reports suggested that redox property involved in the
anti-amyloidogenic activity of a polyphenol [12,23–26]. However,
the molecular mechanism how a polyphenol to inhibit amyloid for-
mation via a redox pathway is still kept unknown. In the present
study, it is evidenced that the formation of quinone intermediates
is a prerequisite for a phenol compound to inhibit amyloid
ﬁbrillation of lysozyme. When incubation at 65 C catechol andA
ED
B
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Fig. 5. SDS–PAGE and NBT-staining assay of lysozyme assemblies prepared in the pre
assemblies prepared by incubating the protein with 100 lg/ml catechol (A), hydroquinon
The NBT-staining results of lysozyme assemblies prepared by incubating the protein with
4, 6, 8, 10, 12 days (lanes 1–8).hydroquinone were oxidized and the resultant quinone intermedi-
ates reacted with the active sites of lysozyme, for instance, the side
chains of lysine, tyrosine, arginine and possibly cysteine. The
modiﬁcation of peptides altered the interacting forces of
intra- and inter-peptide chains. Therefore, the process of amyloid
ﬁbrillation was changed and interrupted.
Previous investigation demonstrated that the oxidative form of
polyphenols showed more potent inhibitory effect on amyloid for-
mation than the reductive form [13]. The authors attributed this
phenomenon to that oxidized polyphenol possessed higher binding
afﬁnity for the growing ends of ﬁbrils than fresh compound. It has
been suggested that quinone or quinonoid substances involved in
the inhibitory role of a polyphenol on amyloid formation [27].
The semiquinone or quinone metabolites formed by EGCG were
found covalently binding to transthyretin [28], a-synuclein [29]
and merozoite surface protein [30], leading to an inhibitory effect
on amyloid ﬁbrillation of the proteins. However, the molecular
mechanism of ﬁbril inhibition by EGCG appears to be complex
and may involve both noncovalent binding and covalent modiﬁca-
tion of the protein. That is, hydrophobic interactions, aromatic
stacking and hydrogen bonding cannot be excluded in the anti-
amyloidogenic effect of EGCG due to the polycyclic structure and
hydrophobic moieties of the molecule. In contrast, the phenolic
compounds tested in this study have a monocyclic structure and
similar hydrophobicity. Considering the fact that phenol and resor-
cinol showed no inhibitory effect in the present study, we suggest
that hydrophobic interactions, aromatic stacking and hydrogen
bonding are not involved in the inhibitory role of catechol and
hydroquinone on amyloid formation. In other words, the formation
of quinone species and subsequently transform lysozyme into
quinoprotein are the main events for catechol and hydroquinone
to inhibit lysozyme amyloid ﬁbrillation.
In conclusion, the present study demonstrated that catechol
and hydroquinone played inhibitory effects on lysozyme ﬁbrilla-
tion. The inhibition of amyloid formation by these two diphenols
was associated with the formation of quinoproteins, similar to
the effect of benzoquinone. In contrast, phenol and resorcinol
showed no effect on lysozyme ﬁbrillation, probably due to that
they cannot be transformed into quinone intermediates under
the condition of the present study. We suggest that quinone inter-
mediates are the active form for phenolic compounds to interrupt
lysozyme amyloid ﬁbrillation. The information of the present study
not only provide a fresh insight into the anti-amyloidogenic role of
polyphenols, but also shed light on a rational design of novel anti-
amyloidogenic drugs with a phenolic structure.F
C
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sence of catechol, hydroquinone and benzoquinone. (A–C) SDS–PAGE of lysozyme
e (B) and benzoquinone (C) at 65 C for 0, 1, 2, 4, 6, 8, 10, 12 days (lanes 1–8). (D–F)
100 lg/ml catechol (D), hydroquinone (E) and benzoquinone (F) at 65 C for 0, 1, 2,
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